Trending:
June 7, 2026, 01:51 PM - 6 min read
Beyond diabetes and obesity, GLP-1 drugs have now earned regulatory approval in several new areas. A trial of more than 17,000 people found semaglutide cut the risk of serious heart attacks and strokes by 20 per cent, even in people without diabetes.
Read more
May 4, 2026, 04:02 PM - 2 min read
“It’s really disheartening. There was a pendulum that swung that was so body acceptance, positivity [and] everybody be who they want to be,” she said.
Read more
December 23, 2025, 02:31 PM - 2 min read
The US food regulator approved a pill version of the GLP-1 drug, Wegovy, that has been developed by Novo Nordisk, which is also its manufacturer
Read more
August 7, 2024, 10:58 AM - 2 min read
Originally developed as a treatment for type 2 diabetes, so-called “skinny jabs” containing the appetite-suppressant semaglutide are a relatively recent innovation.
Read more
July 6, 2024, 12:08 PM - 2 min read
Patients using diabetes and weight-loss drugs Ozempic and Wegovy might face a higher risk of developing a serious eye condition. This condition, called a stroke of the optic nerve or NAION, can lead to blindness, as per new research findings.
Read more